Search
Cardiolipin Biosynthesis CL(10:0/19:0/20:0/i-20:0)
smpdb.ca/view/SMP0178886MetabolicCardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.
Cardiolipin Biosynthesis CL(10:0/20:0/20:0/i-22:0)
smpdb.ca/view/SMP0178979MetabolicCardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.
Cardiolipin Biosynthesis CL(10:0/20:0/i-20:0/22:0)
smpdb.ca/view/SMP0179020MetabolicCardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.
Cardiolipin Biosynthesis CL(10:0/20:0/i-20:0/24:0)
smpdb.ca/view/SMP0179022MetabolicCardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.
Cardiolipin Biosynthesis CL(10:0/a-15:0/20:0/20:0)
smpdb.ca/view/SMP0179682MetabolicCardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.
Cardiolipin Biosynthesis CL(10:0/i-13:0/20:0/20:0)
smpdb.ca/view/SMP0180767MetabolicCardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.
Cardiolipin Biosynthesis CL(10:0/i-14:0/20:0/20:0)
smpdb.ca/view/SMP0181146MetabolicCardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.
Camostat
go.drugbank.com/drugs/DB13729Investigational[A198771,A198777,A193800] Camostat mesylate was first approved in Japan in January 2006.[L13197] … [A193842,A193848] It was first described in the literature in 1981, as part of research on the inhibition of skin tumors in mice.
Phenserine
go.drugbank.com/drugs/DB04892InvestigationalAxonyx announced on 20 September 2005 that phenserine was ineffective in two curtailed phase 3 trials. … Unlike currently marketed AChE inhibitors, it has a dual mechanism of action that also includes anti-amyloid activity, which may confer disease-modifying effects in patients with AD.
KIN-3248
go.drugbank.com/drugs/DB17587InvestigationalIt was designed to mainly target FGFR2 and FGFR3 alterations, which act as oncogenic drivers in 10-20% of cholangiocarcinoma and 20-35% of urothelial cancers, respectively. … Therefore, the broad inhibition of FGFR isoforms may be effective against different types of tumors.